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T
his Health in Action provides 
recommendations for 
improving education for health 
professionals about pharmaceutical 
and device promotion, which includes 
any activity that can increase sales 
of pharmaceuticals or devices. The 
recommendations were produced by 
an iterative E-mail discussion among 
representatives of four organizations: 
the American Medical Student 
Association, Healthy Skepticism Inc., No 
Free Lunch, and PharmAware (Box 1). 
We hope these recommendations 
will inform, stimulate, and support 
educators of health professionals to 
develop improved education about 
pharmaceutical and device promotion. 
We will survey educators to seek their 
views on these recommendations.
Background
In the promotion of rofecoxib (Vioxx), 
“drug marketing got well ahead of the 
science” [1]. The successful hormone-
replacement-therapy marketing 
campaign “convinced physicians that 
so called HRT [hormone-replacement 
therapy] prevented cardiovascular 
disease before one single clinical trial 
with cardiovascular disease end points 
had ever been done” [2]. These are 
just two examples of how misleading 
promotion can be a major threat to 
health [1,2].
There were an estimated 88,000–
140,000 excess cases of serious 
coronary artery disease attributable to 
rofecoxib in the United States alone 
[3]. The number of women harmed 
by severe adverse effects of hormone-
replacement therapy, including breast 
cancer, may have been even larger 
because hormone-replacement therapy 
was used for longer, but we are not 
aware of any reliable estimate. Reforms 
are needed to reduce the risk of similar 
events occurring again [4].
The US Accreditation Council 
for Continuing Medical Education 
states that “residents must learn how 
promotional activities can inﬂ  uence 
judgment in prescribing decisions and 
research activities through speciﬁ  c 
instructional activities” [5]. World 
Health Assembly resolution 52.19 
urges member states to “integrate the 
rational use of drugs and information 
on commercial marketing strategies 
into training for health practitioners 
at all levels.” However, a recent 
worldwide survey of education about 
pharmaceutical promotion in medical 
and pharmacy schools found that “in 
most cases … students devoted one half 
day or less to this topic during their 
professional training; in nearly one 
third of cases, medical faculties devoted 
only 1–2 hours” [6]. That survey also 
found wide variations in objectives, 
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Box 1. The Four Organizations 
Calling for Action
American Medical Student Association 
(http://www.amsa.org) 
An association of nearly 60,000 
doctors-in-training with aims including: 
improving health care and healthcare 
delivery to all people and promoting 
active improvement in medical 
education.
Healthy Skepticism Inc. (http://www.
healthyskepticism.org)
An international organization aiming to 
improve health by reducing harm from 
misleading pharmaceutical promotion.
No Free Lunch (http://www.nofreelunch.
org, http://www.nofreelunch.uk, http://
www.nograziepagoio.it) 
An international network aiming to 
improve patient care by encouraging 
health care providers to practice 
medicine on the basis of scientiﬁ  c 
evidence rather than on the basis of 
pharmaceutical promotion.
PharmAware (http://www.pharmaware.
co.uk)
A group of British medical students who 
aim to change doctors’ relationships with 
the pharmaceutical industry.PLoS Medicine  |  www.plosmedicine.org 1989
ranging from aiming to “increase 
students’ ability to extract beneﬁ  cial 
information from drug promotion” to 
aiming to “increase students’ use of 
independent information sources.”
Recommendations
The American Medical Student 
Association, Healthy Skepticism. Inc., 
No Free Lunch, and PharmAware 
recommend four objectives for 
education about pharmaceutical 
and device promotion (Box 2). We 
recommend that all four objectives 
should be pursued throughout all 
health professionals’ careers: during 
every year of initial professional 
education, specialist training, and 
continuing professional education. 
Education should use methods that 
are effective for changing behavior, 
including interactive experiences and 
involvement of opinion leaders [7]. 
Education for health professionals 
should never, we believe, be funded by 
companies promoting drugs or devices 
[8–12].
Our recommendations are based 
mostly on studies of psychology 
students’ responses to persuasion, 
and medical students’ and physicians’ 
responses to pharmaceutical 
promotion. There is little relevant 
published evidence on the effects of 
promotion on other kinds of health 
professionals or on the promotion of 
devices. These research gaps deserve 
priority. However, the available 
evidence [13–16] leads us to believe 
that our recommendations are 
appropriate for all health professionals 
and are relevant to promotion of all 
therapeutic and diagnostic devices.
Our recommended objectives 
challenge widely held beliefs. 
Consequently, we believe that educators 
should assess and address students’ 
and professionals’ initial beliefs about 
drug and device promotion, so as 
to maximize progress toward the 
beliefs required for appropriate use 
of drugs and devices reﬂ  ected in our 
recommendations below.
All health professionals should be 
educated explicitly about decision 
making and evaluation of evidence 
and promotion. Education for health 
professionals should aim to improve 
the quality of decision making. 
This includes studying the areas of 
psychology, logic, economics, ethics, 
and statistics that are relevant to 
making good decisions, evaluating 
evidence, and evaluating the promotion 
of drugs and devices. For example, 
insights from all those disciplines 
are integrated in an interactive 
educational Web-site module 
produced by Healthy Skepticism Inc., 
for the Royal Australasian College 
of Physicians (http://www.racp.edu.
au). This Web site introduces the 
topics of human decision making and 
vulnerability to persuasion [17–21], 
pharmacoeconomics [22], ethical 
problems arising from gift taking [11], 
and common misunderstandings of 
statistics [23–25].
Health professionals should be 
helped to understand that there is no 
proven method for enabling them to 
gain more beneﬁ  t than harm from 
promotion. There is strong evidence 
that exposure to pharmaceutical 
promotion correlates with medically 
inappropriate and wasteful use of 
pharmaceuticals [26]. However, there 
is a wide range of opinions among 
health professionals about the beneﬁ  t-
to-harm ratio of promotion, and their 
own susceptibility to it. Many believe 
they are capable of distinguishing 
between justiﬁ  ed and unjustiﬁ  ed 
promotional messages. However, 
few health professionals have much 
knowledge of misleading promotional 
techniques, and such knowledge does 
not reliably protect people from being 
misled [18,27].
Resistance to misleading promotion 
can be increased somewhat by helping 
people move from overconﬁ  dence 
in their abilities to understanding 
that they are vulnerable. [27–29]. 
Consequently, education for health 
professionals should explain that while 
knowledge of misleading promotional 
techniques may help them avoid being 
misled sometimes, there is no proven 
method for enabling them to gain 
more beneﬁ  t than harm from exposure 
to pharmaceutical promotion. People 
who are conﬁ  dent in their ability to 
distinguish justiﬁ  ed from unjustiﬁ  ed 
promotional messages may be 
operating under an illusion, as many 
inﬂ  uence techniques are very difﬁ  cult 
for humans to evaluate and there are 
no proven methods for sorting them.
One method for reducing such 
overconﬁ  dence is to ﬁ  rst expose 
participants to a single example of 
misleading drug or device promotion, 
allow them to express unjustiﬁ  ed 
beliefs, debunk those beliefs, and 
then ﬁ  nally explain the misleading 
techniques that were used. This 
method enables participants to 
understand that they are personally 
vulnerable to being misled by 
promotion [18,27]. The aim of this 
method is to decrease conﬁ  dence as 
opposed to the common educational 
objective of increasing conﬁ  dence.
One example of such a strategy 
for reducing conﬁ  dence is an 
educational session held at the 
University of California, Los Angeles, 
in which a university pharmacist was 
introduced to medical students as “a 
pharmaceutical sales representative.” 
The “representative” proceeded to 
mimic standard sales techniques with 
regard to a given drug, while offering 
the students a “free” breakfast. The 
“representative” was then asked to 
leave the room for 20 minutes, to allow 
students to discuss the presentation. 
The “representative” then returned 
to reveal herself as a university 
pharmacist, and to explain and critique 
the techniques that had been used. 
This session was shown to be effective 
in reducing students’ overconﬁ  dence 
in their “skills” at critical appraisal of 
sales representatives [29].
Health professionals should 
be helped to understand their 
responsibility to avoid pharmaceutical 
and device promotion. Because all 
health professionals are vulnerable to 
being misled, we believe that they have 
a professional, ethical, and ﬁ  duciary 
responsibility to patients to take all 
Box 2. Four Objectives 
for Education about 
Pharmaceutical and Device 
Promotion
All health professionals should be aided 
in the following ways:
•  Educated explicitly about decision 
making and evaluation of evidence 
and promotion.
•  Helped to understand that there is 
no proven method for enabling them 
to gain more beneﬁ  t than harm from 
promotion.
•  Helped to understand their 
responsibility to avoid pharmaceutical 
and device promotion.
•  Educated explicitly about the most 
reliable sources of information.
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practical steps to avoid drug and device 
promotion [30–32]. This responsibility 
includes a personal policy of refusing 
to accept personal gifts and one-to-
one visits from sales representatives, 
and supporting organizational policies 
against such practices [33]. Meetings 
of groups of health professionals 
with sales representatives may be less 
harmful than one-to-one meetings, but 
it is unlikely that this type of activity 
will be found to do more good than 
harm compared with no such meetings. 
Education for health professionals 
should not include exposure to 
pharmaceutical or device promotion 
[8,30], except for educational examples 
that are immediately debunked (as 
discussed above).
There is observational evidence 
of beneﬁ  ts from limiting contact 
between pharmaceutical company 
sales representatives and doctors in 
training. In 1992, McMaster University 
implemented a policy that restricted 
interactions between internal medicine 
residents and sales representatives 
during daytime hospital activities. 
This policy included bans on sales 
representatives attending educational 
meetings and a ban on drug company–
funded lunches. Three years after 
training under that policy, internists 
were more skeptical of, and had less 
contact with, sales representatives than 
internists trained before that policy 
or trained at the nearby University of 
Toronto, where there was no policy [34]. 
Other observational studies have found 
that doctors who are more skeptical of 
sales representatives and/or have less-
frequent contact with them tend to be 
more judicious prescribers. [35–39]
Education about the professional 
responsibility to avoid promotion 
should be integrated with hands-on 
education about how to interact with 
others who have different views. This 
is addressed by the American Medical 
Student Association’s PharmFree 
Campaign stepwise module that begins 
in the ﬁ  rst year of medical school and 
continues through residency training. 
This module promotes the vision that 
“all medical students will learn about 
the ethics of drug company interaction 
with health professionals and make the 
rational, informed decision to eschew 
“free” gifts from the pharmaceutical 
industry throughout the training 
career” (http:⁄⁄www.amsa.org/prof/
pharmfree.cfm).
Health professionals should be 
educated explicitly about the most 
reliable sources of information. 
Health professionals should receive 
explicit education about the 
availability, strengths and weaknesses 
of the least-biased, clinically useful 
sources of information, and the 
need to keep themselves up to date 
with the best information sources 
available. This should include use of 
such information as part of routine 
patient care by themselves and by 
role models. Professional associations 
and governments should actively 
develop programs to ensure that these 
sources are readily available to health 
professionals. Health professionals 
should be educated on how to convey 
reliable information to other health 
professionals and to the public, so as 
to provide a superior alternative to 
information from pharmaceutical and 
device companies.
Conclusion
Our recommendations are necessary 
but not sufﬁ  cient for removing the 
adverse inﬂ  uence of promotion 
on health professionals. Improved 
regulation and redesigned incentive 
systems are also needed [4,40]. Our 
recommendations challenge deeply 
held beliefs, so implementation will be 
difﬁ  cult. However, pharmaceutical and 
device promotion causes much more 
harm than is generally realized [26], 
so signiﬁ  cant reforms deserve priority. 
Our hypothesis—that implementing our 
recommendations will lead to improved 
health-care outcomes and earn 
increased public trust in the ability of 
health professionals to provide optimal 
treatment—deserves to be tested.  
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